1 / 4
文档名称:

托伐普坦片治疗收缩性心力衰竭患者的临床效果与安全性 蔺丽媛.pdf

格式:pdf   大小:1,590KB   页数:4页
下载后只包含 1 个 PDF 格式的文档,没有任何的图纸或源代码,查看文件列表

如果您已付费下载过本站文档,您可以点这里二次下载

分享

预览

托伐普坦片治疗收缩性心力衰竭患者的临床效果与安全性 蔺丽媛.pdf

上传人:袭人 2022/7/22 文件大小:1.55 MB

下载得到文件列表

托伐普坦片治疗收缩性心力衰竭患者的临床效果与安全性 蔺丽媛.pdf

相关文档

文档介绍

文档介绍:临床医学研究与实践 2022 年 7 月第 7 卷第 19 期 临床医学
托伐普坦片治疗收y of admission number, the patients were
divided into reference group and experimental group, with 30 cases in each group. The reference group was treated with
furosemide, and the experimental group was treated with tolvaptan tablets. The clinical efficacy, biochemical indexes,
pulmonary vascular indexes, cardiac function indexes, occurence of adverse reactions and inflammatory indexes were
compared between the two groups. Results The total effective rate of treatment in the experimental group was %,
which was significantly higher than % of the reference group (P<). One week after treatment, the K + and Na +
levels in the experimental group were higher than those before treatment and the reference group, while the brain
natriuretic peptide (BNP) level, pulmonary artery pressure and pulmonary capillary pressure were lower than those before
treatment and the reference group (P <). One week after treatment, the left ventricular end -diastolic diameter
(LVEDD), left ventricular end-systolic diameter (LVSD) and heart rate (HR) of the two groups decreased, while cardiac
index (CI) and left ventricular ejection fraction (LVEF) increased, the LVEDD, LVSD and HR of the experimental group
were lowe